Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
JAMA · 28.04.2026 · 335 (16) · 1400
DOI: 10.1001/jama.2026.3277 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 28.04.2026. Verfasst von Nicholas A Marston und 21 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Heart and Vascular Institute, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis.
Objective
To investigate whether evolocumab could prevent a first major cardiovascular event (MACE) in patients without known significant atherosclerosis. Design, Setting, and Participants VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab conducted across 774 sites in 33 countries and enrolling 12 257 patients with no prior myocardial infarction or stroke, LDL-C level 90 mg/dL or greater, and qualifying atherosclerosis or high-risk diabetes. This prespecified subgroup analysis examined outcomes in patients without known significant atherosclerosis (none of the following: prior arterial revascularization, arterial stenosis ≥50%, or coronary artery calcium score ≥100 Agatston units), all of whom had diabetes. Enrollment started in June 2019 and the last patient visit was July 2025, with a median follow-up of 4.8 years.
Intervention
Patients were randomized in a 1:1 ratio to subcutaneous administration of either evolocumab (140 mg every 2 weeks) or matching placebo added to optimally tolerated statin therapy. Main Outcomes and Measures The dual primary end points were composites of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE) and 3-P MACE plus ischemia-driven arterial revascularization (4-P MACE). Secondary end points included all-cause mortality.
Results
This predefined subgroup included 3655 patients (1849 in the evolocumab group and 1806 in the placebo group) with a median age of 65 years (57% female). Among those in the lipid substudy, the median LDL-C level at 48 weeks was 52 mg/dL in the evolocumab group vs 111 mg/dL in the placebo group ( P < .001). A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group (hazard ratio [HR], 0.69 [95% CI, 0.52-0.91]; P = .009; between-group difference, 2.1% [95% CI, 0.4%-3.8%]). A 4-P MACE event occurred in 127 patients (5-year Kaplan-Meier estimate, 7.6%) in the evolocumab group compared with 178 patients (5-year Kaplan-Meier estimate, 10.5%) in the placebo group (HR, 0.69 [95% CI, 0.55-0.86]; P = .001; between-group difference, 2.9% [95% CI, 0.9%-4.9%]). There were 136 deaths (5-year Kaplan-Meier estimate, 7.8%) in the evolocumab group compared with 172 deaths (5-year Kaplan-Meier estimate, 10.1%) in the placebo group (HR, 0.76 [95% CI, 0.61-0.95]). Conclusions and Relevance In high-risk patients without known significant atherosclerosis and with diabetes, evolocumab reduced the risk of a first major cardiovascular event. Trial Registration ClinicalTrials.gov Identifier : NCT03872401
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- TIMI Study Group, Heart and Vascular Institute, Brigham and Women's Hospital, Boston, Massachusetts.
- Amgen Inc, Thousand Oaks, California.
- Cardiology Division, Department of Medical Sciences, University of Torino and Città della Salute e della Scienza, Torino, Italy.
- Division of Endocrinology and Metabolism, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
- Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
- Division of Cardiac Surgery, St Michael's Hospital-Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.
Zitieren
APA
Marston, N. A., Bohula, E. A., Bhatia, A. K., De Ferrari, G. M., Leiter, L. A., Nicolau, J. C., Park, J. G., Murphy, S. A., Walsh, E., Liu, L., Verma, S., Sattar, N., Nicholls, S. J., Lopez-Sendon, J., Gouni-Berthold, I., Tokgozoglu, L., Blankstein, R., Cyrille, M., da Silva Lima, G. P., …, & VESALIUS-CV Investigators (2026). Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes. JAMA, 335(16), 1400. https://doi.org/10.1001/jama.2026.3277
Vancouver
Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes. JAMA. 2026;335(16):1400. doi:10.1001/jama.2026.3277
BibTeX
@article{Marston2026,
author = {Marston, Nicholas A and Bohula, Erin A and Bhatia, Ajay K and De Ferrari, Gaetano M and Leiter, Lawrence A and Nicolau, Jose C and Park, Jeong-Gun and Murphy, Sabina A and Walsh, Emileigh and Liu, Lyrica and Verma, Subodh and Sattar, Naveed and Nicholls, Stephen J and Lopez-Sendon, Jose and Gouni-Berthold, Ioanna and Tokgozoglu, Lale and Blankstein, Ron and Cyrille, Marcoli and da Silva Lima, Gabriel Paiva and Giugliano, Robert P and Sabatine, Marc S and VESALIUS-CV Investigators, VESALIUS-CV Investigators},
title = {Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes},
journal = {JAMA},
year = {2026},
volume = {335},
number = {16},
pages = {1400},
doi = {10.1001/jama.2026.3277}
}
EUVIMED